Healthcare Sales & Marketing Network News: HER2

Searching News Database: HER2

HSMN NewsFeed - 18 Sep 2024
Accord BioPharma, Inc. Announces U.S. Food & Drug Administration Approval of 420mg Strength of HERCESSI(TM) (trastuzumab-strf), a biosimilar to Herceptin(R) (trastuzumab), for the Treatment of Several Forms of HER2-Overexpressing Cancer
Biopharmaceuticals Generics Oncology FDA

HSMN NewsFeed - 21 Aug 2024
PreciseDx Secures $20.7 Million Series B to Advance AI-Powered Cancer Risk Assessments
Diagnostics Oncology Venture Capital

HSMN NewsFeed - 5 Jul 2024
Biostar Pharma Announces FDA Clearance of the IND Application for a Phase 2 Study of Utidelone Injection (UTD1) in HER2- Breast Cancer Brain Metastasis
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 2 May 2024
Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 10 Apr 2024
TORL BioTherapeutics Announces $158 Million Oversubscribed Series B-2 Financing to Advance the Clinical Development of its Novel Antibody-Drug Conjugate (ADC) Oncology Pipeline
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 27 Feb 2024
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 9 Jun 2023
Astellas Submits New Drug Application for Zolbetuximab in Japan
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 8 Dec 2022
Dantari Debuts with $47 Million Series A to Advance Best-in-Class Targeted Medicines for Solid Tumors
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 6 Dec 2022
Caris Life Sciences and Hummingbird Bioscience Enter Into Collaboration to Advance Clinical Development of Anti-HER3 Therapy
Diagnostics Biopharmaceuticals

HSMN NewsFeed - 20 Jul 2022
Nuvalent Announces Leadership Promotions
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 8 Dec 2021
Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-422 for the Treatment of Advanced Breast Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 13 Oct 2021
FDA Approves Verzenio(R) (abemaciclib) as the First and Only CDK4/6 Inhibitor for Certain People with HR+ HER2- High Risk Early Breast Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 6 May 2021
GE Healthcare Acquires Zionexa; Molecular Imaging Agent Aims to Enable More Targeted Treatment for Metastatic Breast Cancer Patients
Diagnostics Radiology Oncology Mergers & Acquisitions

HSMN NewsFeed - 24 Sep 2020
Leap Therapeutics Announces FDA Fast Track Designation Granted to DKN-01 for the Treatment of Gastric and Gastroesophageal Junction Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 27 Jul 2020
CARISMA Therapeutics Announces FDA Clearance of IND Application for First-Ever Engineered Macrophage Immunotherapy
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 22 Jul 2020
Olema Oncology Announces $54 Million Series B Financing
Biopharmaceuticals Oncology Venture Capital Personnel

HSMN NewsFeed - 16 Jun 2020
EXUMA Biotech Adds H. Michael Shepard to Scientific Advisory Board and Steven R. Frank to Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 9 Apr 2020
Bolt Biotherapeutics Appoints Edith Perez, M.D., as Chief Medical Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 5 Feb 2020
Imagion Biosystems Appoints Vice President Clinical & Regulatory Affairs
Diagnostics Oncology Personnel

HSMN NewsFeed - 5 Dec 2019
Black Diamond Therapeutics Closes $85 Million Series C Financing
Biopharmaceuticals Oncology Venture Capital Personnel

HSMN NewsFeed - 4 Sep 2019
NW Bio Expands Senior Management Team With Dr. Kevin Duffy As Vice President, Medical Affairs & External Collaborations
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 30 Jul 2019
Lilly's Verzenio(R) (abemaciclib) Significantly Extended Life in Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Jun 2019
European Radiology Profiles Seno Medical's Ground-Breaking Breast Cancer Diagnostic Technology
Devices Radiology

HSMN NewsFeed - 8 May 2019
Daiichi Sankyo Announces [Fam-] Trastuzumab Deruxtecan Demonstrated Clinically Meaningful Response in Patients with Refractory HER2 Positive Metastatic Breast Cancer, a Population with High Unmet Need
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Apr 2019
Daiichi Sankyo Provides Update on Ongoing FDA Review for Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 25 Feb 2019
FDA Approves Taiho Oncology's LONSURF(R) (trifluridine/tipiracil) for Adult Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 7 Feb 2019
Marker Therapeutics Appoints Mythili Koneru, M.D., Ph.D. as Senior Vice President, Clinical Development
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 14 Jan 2019
Daiichi Sankyo Initiates Pivotal Phase 3 Trial of [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 Low Metastatic Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 18 Dec 2018
Lilly Announces Publication of Analyses Showing Benefit of the Addition of Verzenio(R) (Abemaciclib) in Multiple Subgroups of Patients with Advanced Breast Cancer Identified as Having a More Concerning Prognosis
Biopharmaceuticals Oncology

HSMN NewsFeed - 23 Nov 2018
Precision Oncology Company Guardant Health AMEA announces launch of its Asia, Middle East and Africa regional headquarters in Singapore
Diagnostics Oncology

HSMN NewsFeed - 5 Nov 2018
EMA Validates and Grants Accelerated Assessment of Marketing Authorization Application for Daiichi Sankyo's FLT3 Inhibitor Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 19 Oct 2018
Mylan and Biocon Announce Positive CHMP Opinion for Ogivri(R), Biosimilar Trastuzumab
Biopharmaceuticals Generics Oncology Regulatory

HSMN NewsFeed - 9 Oct 2018
Agendia Announces Level 1 Inclusion of MammaPrint(R) Breast Cancer Test in Updated National Comprehensive Cancer Network(R) (NCCN) Guidelines
Diagnostics Oncology Personalized Medicine

HSMN NewsFeed - 18 Sep 2018
Agendia and Genecast Biotechnology Partner to Launch MammaPrint(R) and BluePrint(R) in China
Diagnostics Personalized Medicine Oncology Product Launch

HSMN NewsFeed - 17 Sep 2018
Halozyme Announces Approval Of Subcutaneous Formulation Of Trastuzumab (Herceptin(R)) In Canada
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 1 Aug 2018
FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo's FLT3 Inhibitor Quizartinib for Relapsed/Refractory FLT3-ITD AML
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 30 Jul 2018
Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 26 Jul 2018
Phase 3 Study Of Subcutaneous Pertuzumab And Trastuzumab Initiated Using Halozyme's ENHANZE(R) Technology
Biopharmaceuticals Oncology Drug Delivery

HSMN NewsFeed - 16 Jul 2018
MEI Pharma Promotes David M. Urso to Chief Operating Office
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 2 Jul 2018
Phase III IMpassion130 Study Showed Genentech's TECENTRIQ Plus Abraxane Significantly Reduced the Risk of Disease Worsening or Death in People With Metastatic or Locally Advanced Triple Negative Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 21 Jun 2018
Caris Life Sciences Presents Data Demonstrating the Ability of ADAPT Biotargeting System to Identify Responders and Non-Responders in a Phase III Pancreatic Cancer Study
Diagnostics Oncology

HSMN NewsFeed - 15 Jun 2018
MEI Pharma Presents Clinical Data on ME-401 at the European Hematology Association Congress
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 May 2018
Daiichi Sankyo Announces Single Agent Quizartinib Significantly Prolongs Overall Survival Compared with Chemotherapy in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations (QuANTUM-R Study)
Biopharmaceuticals Oncology

HSMN NewsFeed - 23 Mar 2018
Amgen And Allergan Receive Positive CHMP Opinion For ABP 980 (Biosimilar Herceptin(R)) For The Treatment Of Three Types Of Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 23 Mar 2018
Caris Life Sciences Announces Published Results Showing that its ADAPT Biotargeting System Effectively Stratified Breast Cancer Patients Based on Their Benefit from Trastuzumab Treatment (Herceptin)
Biopharmaceuticals Diagnostics Oncology

HSMN NewsFeed - 9 Mar 2018
Maura Dickler, M.D., to become Vice President of Late Phase Development at Lilly Oncology
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 11 Dec 2017
Kimberly Blackwell, M.D., to become Vice President of Early Phase Development and Immuno-oncology at Lilly Oncology
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 1 Dec 2017
FDA approves first biosimilar for the treatment of certain breast and stomach cancers
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 12 Oct 2017
FDA Grants Priority Review for Potential New Indication for Lilly's Verzenio(TM) (abemaciclib) as Initial Treatment of Advanced Breast Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 11 Sep 2017
Oncolytics Biotech(R) Announces the Presentation of REOLYSIN(R) Clinical Data at ESMO 2017 Congress
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Aug 2017
FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo's DS-8201 for HER2-Positive Metastatic Breast Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 28 Aug 2017
Daiichi Sankyo Enters Worldwide Licensing Agreement with Boston Pharmaceuticals for a Highly Selective RET Inhibitor for Solid Tumors
Biopharmaceuticals Licensing

HSMN NewsFeed - 31 Jul 2017
Amgen and Allergan Submit Biosimilar Biologics License Application for ABP 980 to US Food and Drug Administration
Biopharmaceuticals Generics Oncology FDA

HSMN NewsFeed - 14 Jul 2017
Biocept Expands Commercial Offering of Clinically Actionable Biomarker Assays with Launch of Liquid Biopsy Test for Progesterone Receptor Detection
Diagnostics Oncology Product Launch

HSMN NewsFeed - 10 Jul 2017
FDA Grants Priority Review for Lilly's Abemaciclib for the Treatment of Advanced Breast Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 21 Jun 2017
Avant Diagnostics Appoints Philippe Goix, PhD, MBA as President & CEO to Commercialize Proprietary Theralink(R) Tumor Biomarker Platform
Diagnostics Oncology Personnel

HSMN NewsFeed - 24 Apr 2017
Lilly Announces Phase 3 MONARCH 3 Breast Cancer Study of Abemaciclib Demonstrated Superior Progression-Free Survival at Interim Analysis
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Apr 2017
Advaxis Appoints Anthony Lombardo as Chief Business Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 3 Apr 2017
MEI Pharma Announces Appointment of Brian Drazba as Chief Financial Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 28 Mar 2017
ONL Therapeutics Strengthens Leadership with Addition to Board of Directors and Expansion of Operations Team
Biopharmaceuticals Ophthalmology Personnel

HSMN NewsFeed - 20 Mar 2017
Lilly Announces Phase 3 MONARCH 2 Breast Cancer Study of Abemaciclib Met Primary Endpoint of Progression-Free Survival
Biopharmaceuticals Oncology

HSMN NewsFeed - 13 Mar 2017
Myriad Genetics Launches the EndoPredict(R) Test in the United States for Patients with Breast Cancer
Diagnostics Oncology Product Launch

HSMN NewsFeed - 17 Feb 2017
LYNPARZA(TM) (olaparib) Meets Primary Endpoint in Phase III Trial in BRCA-Mutated Metastatic Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Dec 2016
Genomic Health Announces Results from Multiple Oncotype DX(R) Studies, Reinforcing its Impact in Delivering Precision Medicine to Breast Cancer Patients Around the World
Diagnostics Personalized Medicine Oncology

HSMN NewsFeed - 10 Nov 2016
IBRANCE(R) (palbociclib) Receives Approval in European Union for the Treatment of Women with HR+/HER2- Metastatic Breast Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 6 Oct 2016
Teva and Celltrion Announce Exclusive Biosimilar Commercial Partnership
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 Aug 2016
Pfizer to Acquire Medivation
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 10 Aug 2016
Lilly Provides Update on MONARCH 2 Phase 3 Trial of Abemaciclib
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Aug 2016
Novartis CDK4/6 Inhibitor LEE011 (Ribociclib) Receives FDA Breakthrough Therapy Designation as First-Line Treatment for HR+/HER2- Advanced Breast Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 19 Jul 2016
TapImmune Appoints Dr. John N. Bonfiglio as President and Chief Operating Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 13 Jul 2016
Lilly and Boehringer Ingelheim Announce Clinical Trial Collaboration in Metastatic Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 12 Jul 2016
Advaxis Appoints Ranya Dajani as Vice President, Corporate Development
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 29 Mar 2016
Oncothyreon Appoints Scott D. Myers Chief Executive Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 27 Jan 2016
Boehringer Ingelheim's Gilotrif(R) Demonstrated Superiority to Iressa(R) (Gefitinib) in Reducing the Risk of Disease Progression and Treatment Failure in First-Line Treatment of Patients with EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 Dec 2015
BIND Therapeutics Appoints Jonathan Yingling, Ph.D., as Chief Scientific Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 7 Dec 2015
Syros Pharmaceuticals Appoints David A. Roth, M.D., as Chief Medical Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 8 Oct 2015
Lilly Receives FDA Breakthrough Therapy Designation for Abemaciclib - a CDK 4 and 6 Inhibitor - in Advanced Breast Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 29 May 2015
Myriad Presents New myRisk(TM) Hereditary Cancer Data at 2015 ASCO Annual Meeting
Diagnostics Oncology

HSMN NewsFeed - 21 Aug 2014
Galena Biopharma Appoints Mark W. Schwartz, Ph.D., as President and Chief Executive Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 25 Jul 2014
Bayer and Onyx Pharmaceuticals Report Phase 3 Trial Results of NEXAVAR(R) (sorafenib) in Patients with Advanced Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Apr 2014
Patrick Roche, Ph.D. Joins HTG Molecular Diagnostics
Diagnostics Personnel

HSMN NewsFeed - 8 Apr 2014
AtheroNova Appoints Dr. Randolph M. Johnson as Chief Operating Officer
Biopharmaceuticals Cardiology Personnel

HSMN NewsFeed - 17 Feb 2014
Published Study Validates Agendia’s MammaPrint Test for Long-Term Prediction of Breast Cancer Outcome
Diagnostics Oncology

HSMN NewsFeed - 3 Feb 2014
Mylan Launches First Trastuzumab Biosimilar, Hertraz(TM), in India
Biopharmaceuticals Product Launch

HSMN NewsFeed - 27 Jan 2014
Pfizer Announces Top-Line Results From Two Phase 3 Trials Of Dacomitinib In Patients With Refractory Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 15 Jan 2014
AbbVie Announces Initiation of Pivotal Phase 3 Study of Veliparib (ABT-888) for Patients with Early-Stage Triple-Negative Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 Nov 2013
ImmunoGen, Inc. Announces Approval of Roche’s Kadcyla(R) in the European Union
Biopharmaceuticals Drug Delivery Oncology Regulatory

HSMN NewsFeed - 4 Oct 2013
MetaStat's MetaSite Breast(TM) Diagnostic Assay Predicts Metastasis in Breast Cancer Study
Diagnostics Oncology

HSMN NewsFeed - 2 Jul 2013
FDA Grants Genentech’s Perjeta Regimen Priority Review for Use Before Surgery in HER2-Positive Early Stage Breast Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 10 May 2013
Curis Announces Approval of Erivedge(R) in Australia
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 26 Apr 2013
Curis Announces Erivedge(R) Receives Positive CHMP Opinion for Conditional Approval in European Union
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 10 Apr 2013
Pfizer’s Palbociclib (PD-0332991) Receives Food And Drug Administration Breakthrough Therapy Designation For Potential Treatment Of Patients With Breast Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 19 Feb 2013
Curis Appoints Ali Fattaey, Ph.D. as President and Chief Operating Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 4 Dec 2012
Galena Biopharma Announces Signature of Commercialization Partnership With Teva for Israel
Biopharmaceuticals Oncology

HSMN NewsFeed - 28 Nov 2012
Curis Announces Worldwide In-Licensing of IAP Inhibitor GDC-0917 From Genentech
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 1 Oct 2012
Genentech’s Trastuzumab Emtansine (T-DM1) Significantly Extended Survival in People With Aggressive Form of Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 25 Sep 2012
Life Technologies Launches Pervenio(TM) Lung RS, a Risk Stratification Test for Early Stage Lung Cancer
Diagnostics Oncology

HSMN NewsFeed - 17 Sep 2012
Pfizer To Present New Data in Lung And Kidney Cancers at The European Society For Medical Oncology 2012 Congress
Biopharmaceuticals Oncology

HSMN NewsFeed - 30 Aug 2012
Genmab Enters Worldwide Agreement With Janssen for Daratumumab
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 10 Jul 2012
Agendia Welcomes Dr. Mark Gittleman to Expanding Medical Advisory Board
Diagnostics Personalized Medicine Oncology Personnel

HSMN NewsFeed - 9 Jul 2012
Agendia Names Industry Veteran Glen Fredenberg CFO and Vice President of Finance
Diagnostics Personalized Medicine Oncology Personnel

HSMN NewsFeed - 22 Jun 2012
New Data From Phase III Study Showed That People With HER2-Positive Metastatic Breast Cancer Lived Longer With Genentech’s Perjeta
Biopharmaceuticals Oncology

HSMN NewsFeed - 1 Jun 2012
Agendia Announces Launch of ColoPrint for Colon Cancer Prognosis and Prediction
Diagnostics Personalized Medicine Oncology

HSMN NewsFeed - 16 May 2012
Genentech Will Report New Data on Important Progress for People with Advanced Cancers at ASCO 2012
Biopharmaceuticals Oncology

HSMN NewsFeed - 7 May 2012
Ventana Receives FDA Clearance for p53 (DO-7) Image Analysis and Digital Read Applications
Diagnostics FDA

HSMN NewsFeed - 27 Apr 2012
New Drug Application for Arzerra Submitted in Japan
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 16 Apr 2012
Mayo Clinic Breast Cancer Study Finds New Type of Mutation
Diagnostics Oncology

HSMN NewsFeed - 30 Mar 2012
Genentech’s Trastuzumab Emtansine (T-DM1) Showed Positive Phase III Results In HER2-Positive Metastatic Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 Mar 2012
Synta Announces Appointment of George Farmer, Ph.D., as Vice President, Corporate Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 22 Mar 2012
First-Ever Prospective Diagnostic Study in Breast Cancer
Diagnostics Oncology

HSMN NewsFeed - 19 Mar 2012
Genmab Provides Update on Ofatumumab Phase III Head to Head Study in DLBCL
Biopharmaceuticals Oncology

HSMN NewsFeed - 12 Mar 2012
Synta Announces Appointment of Dvorit Samid, Ph.D., as Vice President, Medical Affairs
Biopharmaceuticals Personnel

HSMN NewsFeed - 20 Feb 2012
FDA Clears ASI’s GenASIs Advanced Imaging for HER-2/neu Analysis
Diagnostics Oncology FDA

HSMN NewsFeed - 20 Jan 2012
Galena Biopharma Initiates Patient Enrollment in NeuVax(TM) Phase 3 PRESENT Trial to Prevent Breast Cancer Recurrence
Biopharmaceuticals Oncology

HSMN NewsFeed - 6 Dec 2011
Agendia Introduces the SYMPHONY(TM) Breast Cancer Profile With Paraffin Embedded Tissue
Diagnostics Personalized Medicine Oncology

HSMN NewsFeed - 8 Nov 2011
Curis Announces Appointment of Maurizio Voi, M.D. as Chief Medical and Chief Development Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 18 Oct 2011
Halozyme Announces Positive Results from Roche's Subcutaneous Herceptin Phase 3 Trial
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Oct 2011
Galena Biopharma Hires Hana B. Moran as Vice President, Regulatory Affairs and Compliance
Biopharmaceuticals Personnel

HSMN NewsFeed - 15 Sep 2011
Curis, Inc. Announces Appointment of Robert Martell, M.D., Ph.D. to its Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 2 Aug 2011
Study Shows Positron Emission Mammography (PEM) May Help Predict Breast Cancer Survival By Identifying Most Aggressive Cancers
Devices Radiology

HSMN NewsFeed - 25 Jul 2011
St. Gallen International Breast Cancer Expert Panel Guidelines Include Oncotype DX(R) as Predictor of Chemotherapy Benefit
Diagnostics Personalized Medicine Oncology

HSMN NewsFeed - 15 Jul 2011
Pertuzumab Combined With Herceptin and Chemotherapy Significantly Extended the Time People With HER2-Positive Metastatic Breast Cancer Lived Without Their Disease Getting Worse
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 Mar 2011
Apthera and RXi Pharmaceuticals Announce Definitive Merger Agreement
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 31 Mar 2011
RXi Pharmaceuticals Aggressively Moves into Late-Stage Clinical Development with the Agreement to Acquire Apthera, Inc.
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 24 Feb 2011
FDA Grants Genentech a Hearing on Avastin’s Use for Metastatic Breast Cancer in the United States
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 24 Feb 2011
Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Feb 2011
Oncos Therapeutics Increases Clinical Momentum With Appointment of Chief Medical Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 16 Dec 2010
Genentech Provides Update on Avastin for Metastatic Breast Cancer Following Reviews in Europe and the United States
Biopharmaceuticals Oncology

HSMN NewsFeed - 10 Dec 2010
Pertuzumab and Herceptin Plus Chemotherapy Significantly Improved the Rate of Complete Tumor Disappearance in Study of Women With Newly Diagnosed, Early-Stage HER2-Positive Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Dec 2010
Study Shows Novartis Drug Afinitor(R) Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 Aug 2010
Genentech Provides Update on FDA Application for T-DM1
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 16 Jul 2010
GTC Biotherapeutics Regains US Rights to ATryn(R) ; the First Recombinant Antithrombin Product Approved in the World
Biopharmaceuticals

HSMN NewsFeed - 7 Jul 2010
Genentech Submits Application to FDA for Trastuzumab-DM1 in Previously Treated Advanced HER2-Positive Breast Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 16 Jun 2010
GTC Biotherapeutics Announces New $7 Million Financing, Company Restructuring and Management Changes
Biopharmaceuticals Personnel

HSMN NewsFeed - 8 Jun 2010
Myriad Pharmaceuticals Announces Intent to Focus on Oncology Portfolio
Biopharmaceuticals Oncology

HSMN NewsFeed - 26 May 2010
Researchers at MD Anderson Show That Positron Emission Mammography (PEM) Helps Evaluate Early Response to Neoadjuvant Chemotherapy
Devices Radiology Oncology

HSMN NewsFeed - 23 Apr 2010
Genentech Submits Supplemental Application to FDA for Herceptin in Advanced HER2-Positive Stomach Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Apr 2010
Myriad Pharmaceuticals Announces Termination of Merger Agreement With Javelin Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 12 Apr 2010
Myriad Pharmaceuticals Receives Notice of Javelin's Intent to Terminate Merger Agreement
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 25 Mar 2010
Declaratory Relief Complaint for Patent Infringement Under Patent Based on Manufacture, Marketing and Sale of Arzerra
Biopharmaceuticals Oncology Litigation

HSMN NewsFeed - 17 Mar 2010
New Data Indicate Effectiveness of Clarient's Ovotax(TM) Test for Ovarian Cancer
Diagnostics Personalized Medicine Oncology

HSMN NewsFeed - 23 Feb 2010
Phase III Study of Avastin Plus Chemotherapy in Advanced Stomach Cancer Did Not Meet Primary Endpoint
Biopharmaceuticals Oncology

HSMN NewsFeed - 30 Jan 2010
GSK's TYKERB(R) Receives Accelerated Approval for First-Line Combination Treatment of Metastatic Breast Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 22 Jan 2010
Arzerra(TM) (Ofatumumab) Receives Positive Opinion for Conditional Approval in Europe for Refractory Chronic Lymphocytic Leukaemia
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 8 Jan 2010
Dr. Mark W. Schwartz Joins Apthera as President & CEO
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 7 Jan 2010
Sopherion Therapeutics Receives FDA Fast Track Designation for Myocet in Metastatic Breast Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 18 Dec 2009
Myriad Pharmaceuticals to Acquire Javelin Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 17 Nov 2009
Genentech Submits Supplemental Applications to FDA for Avastin Combined with Commonly Used Chemotherapies for Women with Advanced Breast Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 8 Oct 2009
Declaratory Judgment Action Filed by GSK
Biopharmaceuticals Litigation

HSMN NewsFeed - 30 Sep 2009
Results Reported for Exploratory Phase 2 Study of Nexavar in Combination With Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 26 Aug 2009
Genmab Announces Positive Top-Line Results for Arzerra(TM) in Front Line NHL
Biopharmaceuticals Oncology

HSMN NewsFeed - 24 Aug 2009
Aperio Receives Second FDA Clearance for HER2 Image Analysis Application for Breast Cancer
Diagnostics Oncology FDA

HSMN NewsFeed - 18 Aug 2009
Avastin Plus Commonly Used Chemotherapies Improved Progression-Free Survival (PFS) in Women with Previously Treated Advanced Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 10 Jul 2009
Ipsogen Reports Incorporation of the Genomic Grade in the 2009 St. Gallen International Consensus Meeting on the Primary Treatment of Early Breast Cancer
Diagnostics Oncology

HSMN NewsFeed - 1 Jul 2009
Myriad Pharmaceuticals, Inc. Established as an Independent Pharmaceutical Development Company
Biopharmaceuticals

HSMN NewsFeed - 4 Jun 2009
Apthera Announces Product License Agreement With Kwang Dong Pharmaceutical Co., Ltd.
Biopharmaceuticals Oncology Licenisng

HSMN NewsFeed - 7 May 2009
Ipsogen Launches a New Test to Guide Hormonotherapy Prescription in Breast Cancer
Diagnostics Oncology

HSMN NewsFeed - 5 May 2009
FDA Grants Accelerated Approval of Avastin for Brain Cancer (Glioblastoma) That Has Progressed Following Prior Therapy
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 5 May 2009
Clarient Launches New Breast Cancer Test
Diagnostics Oncology

HSMN NewsFeed - 22 Apr 2009
Phase III C-08 Study of Avastin in Early-Stage Colon Cancer Did Not Meet Primary Endpoint
Biopharmaceuticals Oncology

HSMN NewsFeed - 23 Feb 2009
Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 23 Feb 2009
Bavarian Nordic Updates on Phase I/II Studies With Breast Cancer Vaccine
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Feb 2009
GlaxoSmithKline and Genmab Seek European Marketing Authorisation of Arzerra (Ofatumumab) in Advanced Stage Blood Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 22 Dec 2008
Myriad Genetics Launches Sixth Personalized Medicine Product, Prezeon -- to Reveal PTEN Status
Diagnostics Oncology

HSMN NewsFeed - 23 Nov 2008
Avastin Plus Commonly Used Chemotherapies Demonstrated Improved Progression-Free Survival In Advanced Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 28 Oct 2008
Ikonisys Receives FDA Clearance for Non-Invasive, HER-2 Breast Cancer Test
Diagnostics Oncology FDA

HSMN NewsFeed - 15 Sep 2008
Invitrogen, Biocare to Market FDA Approved Breast Cancer Test
Diagnostics FDA

HSMN NewsFeed - 4 Sep 2008
Agendia Launches TargetPrint(R) for Breast Cancer Patients
Diagnostics Oncology

HSMN NewsFeed - 30 Aug 2008
Monoclonal Antibody Sales to Almost Double in Coming Years
Biopharmaceuticals

HSMN NewsFeed - 8 Jul 2008
Monogram Announces Commercial Availability of the HERmark(TM) Breast Cancer Assay
Diagnostics Oncology

HSMN NewsFeed - 2 Jun 2008
ABRAXANE(R) in Combination with Trastuzumab and Carboplatin Evaluated as First-Line Treatment for Patients with HER2-Positive Metastatic Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 1 Jun 2008
New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 May 2008
Kosan Appoints Pamela S. Cohen, M.D., as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 14 Apr 2008
Low HER2 Expressing Breast Cancer Patients Respond Preferentially to Apthera's NeuVax(TM)
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 Mar 2008
Oncology Researcher Forecasts Increased Use of Predictive Medicine at NCCN Conference
Diagnostics Oncology

HSMN NewsFeed - 25 Mar 2008
Monogram Announces Promotion of Gordon Parry, PhD, to Vice President, Research and Development, Oncology
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 10 Mar 2008
Curis Announces Conclusion of Hedgehog Agonist Collaboration with Wyeth
Biopharmaceuticals

HSMN NewsFeed - 23 Feb 2008
FDA Grants Accelerated Approval of Avastin in Combination With Paclitaxel Chemotherapy for First-Line Treatment of Advanced HER2-Negative Breast Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 22 Jan 2008
Apthera Files a Phase III Special Protocol Assessment with FDA for NeuVax(TM) in Early-Stage Breast Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 Jan 2008
Aperio Receives FDA Clearance for Manual Read of HER2 Digital Slides
Diagnostics FDA

HSMN NewsFeed - 3 Jan 2008
Kosan Appoints Helen S. Kim as Chief Business Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 17 Dec 2007
GlaxoSmithKline Announces Data on TYKERB(R) (Lapatinib) Plus Capecitabine for the Treatment of HER2 Positive Breast Cancer Brain Metastases
Biopharmaceuticals Oncology

HSMN NewsFeed - 15 Dec 2007
Xeloda(R), Taxotere(R) and Herceptin(R) Combination Study Suggests Clinical Benefit in Invasive Breast Cancer with Shortened Treatment Cycle
Biopharmaceuticals Oncology

HSMN NewsFeed - 13 Dec 2007
Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Dec 2007
Genentech Provides Update from Avastin FDA Advisory Meeting
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 16 Oct 2007
FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 3 Oct 2007
Ventana Submits INFORM(TM) HER2 SISH DNA Probe Assay for FDA Approval
Diagnostics Oncology FDA

HSMN NewsFeed - 7 Sep 2007
Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Sep 2007
Roche's Tarceva(R) Delivers Longer Life for Lung Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 24 Aug 2007
Genentech Announces Resubmission of Supplemental Biologics License Application for Avastin in Combination with Paclitaxel for First-Line Metastatic Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Jun 2007
New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2007
Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Jun 2007
ImmunoGen, Inc. Announces Clinical Data Reported at ASCO
Biopharmaceuticals Drug Delivery Oncology

HSMN NewsFeed - 3 Jun 2007
Genentech Provides Update on Pipeline Agents at the American Society of Clinical Oncology Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Jun 2007
Glaxosmithkline Reports Positive New Data on Tykerb(R)(Lapatinib) at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Jun 2007
Xeloda(R) Plus Avastin(R) Combination Delays Disease Progression in Women with Advanced Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 30 May 2007
New Data Highlighting ABRAXANE as Single Agent and in Combination for the Treatment of Breast, Lung and Ovarian Cancers to Be Presented at ASCO
Biopharmaceuticals Drug Delivery Oncology

HSMN NewsFeed - 15 May 2007
Senior Development Executive Joins Serenex
Biopharmaceuticals Personnel

HSMN NewsFeed - 17 Apr 2007
AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and Drug-Resistant Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 14 Mar 2007
Tragara Pharmaceuticals, Inc. Announces Corporate Launch and Series A Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 13 Mar 2007
FDA Approves TYKERB(R) (lapatinib) in Combination With Xeloda(R) (capecitabine) for the Treatment of Advanced or Metastatic Breast Cancer in Women Who Have Progressed on Prior Therapy
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 8 Mar 2007
VMSI Launches Automated HER2 Silver for Breast Cancer Pathology
Diagnostics Oncology

HSMN NewsFeed - 26 Feb 2007
GSK Initiates First Global Phase III Study of TYKERB(R) (lapatinib) in Head and Neck Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 18 Jan 2007
Ventana Receives FDA Approval for Rabbit Monoclonal Antibody
Diagnostics Oncology FDA

HSMN NewsFeed - 8 Jan 2007
NCCN Offers HER2 Testing for Breast Cancer Patients(TM)
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jan 2007
AVEO Acquires Clinical Stage Anti-Cancer Compound From Kirin
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 3 Jan 2007
Kosan Appoints Jane Green as Vice President, Corporate Communications
Biopharmaceuticals Personnel

HSMN NewsFeed - 28 Dec 2006
Landmark Tykerb(R) (Lapatinib) Data Published in the New England Journal of Medicine
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 Dec 2006
Kosan Announces License of Motilin Agonist Program to Pfizer
Biopharmaceuticals Licensing

HSMN NewsFeed - 18 Dec 2006
Anthracyclines May Not Be for Everyone: Report From the 29th Annual San Antonio Breast Cancer Symposium
Biopharmaceuticals Oncology

HSMN NewsFeed - 15 Dec 2006
Progress Reported Toward Development of a Breast Cancer Vaccine
Biopharmaceuticals Oncology

HSMN NewsFeed - 15 Dec 2006
Xeloda(R) Plus Avastin(R) Combination May Produce Clinical Benefit in Patients with Advanced Breast Cancer
Biopharmaceuticaals Oncology

HSMN NewsFeed - 14 Dec 2006
New Data On Pfizer's Aromasin and Ellence to Be Presented at San Antonio Breast Cancer Symposium
Biopharmaceuticals Oncology

HSMN NewsFeed - 14 Dec 2006
Data Presented Today Show ARIMIDEX(R) Combined With Herceptin(R) Extended Progression-Free Survival in Patients With Advanced HER-2-Positive and Hormone Receptor-Positive Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 14 Dec 2006
HER2/neu Vaccine Results Spurs Phase III Planning by Apthera, Inc.
Biopharmaceuticals Oncology

HSMN NewsFeed - 13 Dec 2006
Lapatinib (Tykerb(R)) to be Evaluated in Early Stage Disease in Adjuvant Breast Cancer Settings Internationally
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 Nov 2006
FDA Approves Herceptin(R) for the Adjuvant Treatment of HER2-Positive Node-Positive Breast Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 26 Oct 2006
Kosan Appoints Robert De Jager as Chief Medical Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 2 Oct 2006
Patients With HER2-Positive Breast Cancer Significantly Benefit From Addition of Xeloda to Herceptin and Taxotere Therapy
Biopharmaceuticals Oncology

HSMN NewsFeed - 25 May 2006
Genentech Submits Supplemental Biologics License Application for Avastin With Chemotherapy in First-Line Metastatic Breast Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 24 May 2006
GlaxoSmithKline Demonstrates Progress of Oncology Portfolio; New Data to Be Presented at ASCO 2006
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 May 2006
ImmunoGen, Inc. to Develop Commercial-Scale Manufacturing Process for Trastuzumab-DM1 for Genentech
Biopharmaceuticals

Return to NewsFeed

Additional items found! 58

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 58 additional stories matching:
HER2
(Password required)

FindReps - available on the Apple App Store for iPhone and iPad.